Современные подходы к лечению и профилактике тромботических осложнений в онкологии

1. Trousseau A. Phlegmasia alba dolens. In: Trousseau A, ed. Clinique medicale de l'Hotel-Dieu de Paris. Bailliеre: Paris, 1865; p. 654–712.
2. Peuscher FW. Thrombosis and bleeding in cancer patients. Neth J Med 1981; 24: 23–35.
3. Beer JH, Haeberli A, Vogt A, Woodtli K et al. Coagulation markers predict survival in cancer patients. Thromb Haemost 2002; 88: 745–9.
4. Miller GJ, Bauer KA, Howarth DJ et al. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004; 2: 2107–14.
5. Khorana AA, Francis CW, Culakova E. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632–4.
6. Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 2000; 160: 809–15.
7. Caine GJ, Stonelake PS, Lip GY et al. The hypercoagulable state of malignancy: Pathogenesis and current debate. Neoplasia 2002; 4: 465–73.
8. Gomes MP, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Huntingt) 2003; 17: 126–35, discussion 139–44.
9. Stein PD, Beemath A, Meyers FA et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119: 60–8.
10. Sorensen HT, Mellemkjaer L, Olsen JH et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846–50.
11. Elting LS, Escalante CP, Cooksley C et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164: 1653–61.
12. Blom JW, Doggen CJ, Osanto S et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–22.
13. Levitan N, Dowlati A, Remick SC et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285–91.
14. Khorana AA, Francis CW, Culakova E et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484–90.
15. Cavo M, Zamagni E, Cellini C et al. Deepvein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002; 100: 2272–3.
16. Decensi A, Maisonneuve P, Rtmensz N et al. Effect of tamoxifen on venous tromboembolic events in a breast cancer prevention. Circulation 2005; 111: 650–6.
17. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including9353 patients. J Natl Cancer Inst 2006; 98: 708–14.
18. Barbui T, Finazzi G, Grassi A et al. Thrombosis in cancer patients treated with hematopoietic growth factors-a meta-analysis: On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1996; 75: 368–71.
19. Khorana AA, Francis CW, Culakova E et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observationalstudy. Cancer 2005; 104: 2822–9.
20. Abramson N, Costantino JP, Garber JE et al. Effect of Factor V Leiden and prothrombin G20210- A mutations on thromboembolic risk in the National Surgical Adjuvant Breast and Bowel ASCO Guideline on VTE and Treatment in Patients With Cancer www.jco.org 13 Project Breast Cancer Prevention trial. J Natl Cancer Inst 2006; 98: 904–10.
21. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S–400S.
22. Clarke-Pearson DL, Synan IS, Hinshaw WM et al. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984; 63: 92–8.
23. Roderick P, Nicholson T, Armitage A et al: An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales. Health Technol Assess 2005; 9: 1–178.
24. Gallus AS, Hirsh J, O'Brien SE et al: Prevention of venous thrombosis with small, subcutaneous doses of heparin. JAMA 1976; 235: 1980–2.
25. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: Results of meta-analysis. Ann Surg 1988; 208: 227–40.
26. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: An international multicentre trial. Lancet 1975; 2: 45–51.
27. Bergqvist D, Burmark US, Flordal PA et al Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995; 82: 496–501.
28. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A doubleblind randomized multicentre trial with venographic assessment – ENOXACAN Study Group. Br J Surg 1997; 84: 1099–103.
29. Deitcher SR. Primary prevention of venous thromboembolic events (VTE) in cancer patients: An American survey study. J Clin Oncol 2004; 22: 750s, (suppl; abstr 8086).
30. Wille-Jorgensen P, Rasmussen MS, Andersen BR et al. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery. Cochrane Database Syst Rev 2003; 4: CD001217.
31. Rasmussen NS, Jorgensen NL, Wille-Jorgensen P et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006; 4 (11): 2384–90.
32. Bergqvist D, Agnelli G, Cohen AT et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975–80.
33. Leizorovicz A, Cohen AT, Turpie AGG et al A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study [abstract]. J Thromb Haemost 2003; 1 (suppl.): OC396.
34. Samama MM, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793–800.
35. McGarry LJ, Stokes ME, Thompson D et al. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients: a retrospective database analysis. Thromb J 2006; 4 (1): 1.
36. Cohen AT, Davidson BL, Gallus AS et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332 (7537): 325–9.
37. Jarrett BP, Dougherty MJ, Calligaro KD. Inferior vena cava filters in malignant disease. J Vasc Surg 2002; 36: 704–7.
38. Decousus H, Leizorovicz A, Parent F et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998; 338: 409–15.
39. Levine M, Hirsh J, Gent M et al. Doubleblind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886–9.
40. Haas SK. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer: Results of the TOPIC Studies. J Thromb Haemost 2005; 3.
41. Rajkumar SV, Blood E, Vesole D et al. Phase III clinical trial of thalidomide plus dexamethasonecompared with dexamethasone alone in newly diagnosed multiple myeloma: A c linical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–6.
42. Zangari M, Anaissie E, Barlogie B et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614–5.
43. Bennett CL, Angelotta C, Yarnold PR et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006; 296: 2558–60.
44. Zonder JA, Barlogie B, Durie BG et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomidea nd dexamethasone: Benefit of aspirin prophylaxis. Blood 2006; 108: 403.
45. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) withFU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60–5.
46. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.
47. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lungcancer. J Clin Oncol 2004; 22: 2184–91.
48. Wan S, Qunlan DJ, Agnelli G et al. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism a meta-analysis of control trials. Circulation 2004; 110: 744–9.
49. Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484–8.
50. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078–83.
51. Lee AY, Levine MN, Baker RI et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–15.
52. Hull R, Pineo GF, Mah A et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119 (12): 1062–72.
53. Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992; 339: 1476.
54. Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269–77.
55. Wang A, Templeton DM. Inhibition of mitogenesis and c-fos induction in mesangial cells by heparin and heparan sulfates. Kidney Int 1996; 49 (2): 437–48.
56. Folkman J, Weisz PB, Joullie MM et al. Control of angiogenesis with synthetic heparin substitutes. Science 1989; 243: 1490–3.
57. Collen A, Koolwijk P, Kroon ME, van Hinsbergh VWM. The influence of fibrin structure on the formation and maintenance of capillary-like tubules. Angiogenesis 1998; 2: 153–65.
58. Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004; 92: 627–33.
59. Wahrenbrock M, Borsig L, Le D et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas J Clin Invest 2003; 112 (6): 853–62.
60. Biggerstaff JP, Seth N, Amirkhosravi A et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo and enhances experimental metastasis. Clin Exp Metastasis 1999; 17: 723–90.
61. Clifton EE, Agostino D. Factors affecting the development of metastatic cancer. Cancer 1962; 15: 276–83.
62. Lee AE, Rogers LA, Jeffery RE, Longcroft JM. Comparison of metastatic cell lines derived from a murine mammary tumour, and reduction of metastasis by heparin. Clin Exp Metastasis 1988; 6: 463–71.
63. Angelini A, Di Febbo C, Ciofani G et al. Inhibition of P-Glycoprotein-mediated multidrug resistance by unfractionated heparin: a new potential chemosensitizer for cancer therapy. Cancer Biol Ther 2005; 4: 313–7.
64. Lee AYY, Rickles FR, Julian JA et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123–9.
65. Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004; 22: 1944–8.
66. Klerk CPW, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130–5.
67. Sideras K, Shaefer PL, Okuno SH et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proc 2006; 81 (6): 758–67.
68. Altinbas M, Coskun HS, Er O et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 1266–71.
69. Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer JCO 2007; 25: 5490–505.

В.В.Птушкин

Отдел подростковой и возрастной гематологии и онкологии ФГУ ФНКЦ ДГОИ Росздрава, Москва